Gilbert’s syndrome is the most common hereditary cause of elevated bilirubin levels and can be found in up to 5% of the population. It is characterized by an isolated increase in unconjugated bilirubin without any detectable liver disease. In most cases, it is inherited in an autosomal recessive manner, although there have been some instances of autosomal dominant inheritance, particularly in Asian populations.

The elevated bilirubin levels in Gilbert’s syndrome do not have any serious consequences and typically occur during times of stress, physical exertion, fasting, or infection. While it is often asymptomatic, some individuals may experience symptoms such as fatigue, decreased appetite, nausea, and abdominal pain.

The underlying cause of the elevated bilirubin levels is a decrease in the activity of the enzyme glucuronyltransferase, which is responsible for conjugating bilirubin. In Gilbert’s syndrome, the bilirubin levels are generally less than three times the upper limit of normal, with more than 70% of the bilirubin being unconjugated. Liver function tests and LDH (lactate dehydrogenase) levels are typically within the normal range.

Fluid deficit in children and young people with severe diabetic ketoacidosis (DKA) is determined by measuring their blood pH and bicarbonate levels. If the blood pH is below 7.1 and/or the bicarbonate level is below 5, it indicates a fluid deficit. This simplified explanation uses a cutoff value of 5 to determine the severity of the fluid deficit in DKA.

Further Reading:

Diabetic ketoacidosis (DKA) is a serious complication of diabetes that occurs due to a lack of insulin in the body. It is most commonly seen in individuals with type 1 diabetes but can also occur in type 2 diabetes. DKA is characterized by hyperglycemia, acidosis, and ketonaemia.

The pathophysiology of DKA involves insulin deficiency, which leads to increased glucose production and decreased glucose uptake by cells. This results in hyperglycemia and osmotic diuresis, leading to dehydration. Insulin deficiency also leads to increased lipolysis and the production of ketone bodies, which are acidic. The body attempts to buffer the pH change through metabolic and respiratory compensation, resulting in metabolic acidosis.

DKA can be precipitated by factors such as infection, physiological stress, non-compliance with insulin therapy, acute medical conditions, and certain medications. The clinical features of DKA include polydipsia, polyuria, signs of dehydration, ketotic breath smell, tachypnea, confusion, headache, nausea, vomiting, lethargy, and abdominal pain.

The diagnosis of DKA is based on the presence of ketonaemia or ketonuria, blood glucose levels above 11 mmol/L or known diabetes mellitus, and a blood pH below 7.3 or bicarbonate levels below 15 mmol/L. Initial investigations include blood gas analysis, urine dipstick for glucose and ketones, blood glucose measurement, and electrolyte levels.

Management of DKA involves fluid replacement, electrolyte correction, insulin therapy, and treatment of any underlying cause. Fluid replacement is typically done with isotonic saline, and potassium may need to be added depending on the patient’s levels. Insulin therapy is initiated with an intravenous infusion, and the rate is adjusted based on blood glucose levels. Monitoring of blood glucose, ketones, bicarbonate, and electrolytes is essential, and the insulin infusion is discontinued once ketones are below 0.3 mmol/L, pH is above 7.3, and bicarbonate is above 18 mmol/L.

Complications of DKA and its treatment include gastric stasis, thromboembolism, electrolyte disturbances, cerebral edema, hypoglycemia, acute respiratory distress syndrome, and acute kidney injury. Prompt medical intervention is crucial in managing DKA to prevent potentially fatal outcomes.

Clostridium difficile infections can range in severity from mild to life-threatening. Mild or moderate severity infections are determined by the frequency of stool and white blood cell count. Severe or life-threatening infections are characterized by high fever, radiological signs, and evidence of organ dysfunction or sepsis.

In this case, the patient’s clinical features indicate a moderate severity C.diff infection. Moderate severity infections typically have an increased white blood cell count but less than 15 x 109/l. They are typically associated with 3-5 loose stools per day.

Further Reading:

Clostridium difficile (C.diff) is a gram positive rod commonly found in hospitals. Some strains of C.diff produce exotoxins that can cause intestinal damage, leading to pseudomembranous colitis. This infection can range from mild diarrhea to severe illness. Antibiotic-associated diarrhea is often caused by C.diff, with 20-30% of cases being attributed to this bacteria. Antibiotics such as clindamycin, cephalosporins, fluoroquinolones, and broad-spectrum penicillins are frequently associated with C.diff infection.

Clinical features of C.diff infection include diarrhea, distinctive smell, abdominal pain, raised white blood cell count, and in severe cases, toxic megacolon. In some severe cases, diarrhea may be absent due to the infection causing paralytic ileus. Diagnosis is made by detecting Clostridium difficile toxin (CDT) in the stool. There are two types of exotoxins produced by C.diff, toxin A and toxin B, which cause mucosal damage and the formation of a pseudomembrane in the colon.

Risk factors for developing C.diff infection include age over 65, antibiotic treatment, previous C.diff infection, exposure to infected individuals, proton pump inhibitor or H2 receptor antagonist use, prolonged hospitalization or residence in a nursing home, and chronic disease or immunosuppression. Complications of C.diff infection can include toxic megacolon, colon perforation, sepsis, and even death, especially in frail elderly individuals.

Management of C.diff infection involves stopping the causative antibiotic if possible, optimizing hydration with IV fluids if necessary, and assessing the severity of the infection. Treatment options vary based on severity, ranging from no antibiotics for mild cases to vancomycin or fidaxomicin for moderate cases, and hospital protocol antibiotics (such as oral vancomycin with IV metronidazole) for severe or life-threatening cases. Severe cases may require admission under gastroenterology or GI surgeons.

This patient is displaying symptoms consistent with a malabsorption syndrome, which is supported by the findings of subtotal villous atrophy in his small bowel biopsy. Based on this information, the possible causes can be narrowed down to tropical sprue, coeliac disease, and giardiasis.

Considering that the patient was previously healthy before his trip to Nepal, it is unlikely that he has coeliac disease. Additionally, tropical sprue is rare outside of the regions around the equator and is uncommon in Nepal. On the other hand, giardiasis is prevalent in Nepal and is the most probable cause of the patient’s symptoms.

Giardiasis is a chronic diarrheal illness caused by a parasite called Giardia lamblia. Infection occurs when individuals ingest cysts present in contaminated food or water. Common symptoms associated with giardiasis include chronic diarrhea, weakness, abdominal cramps, flatulence, smelly and greasy stools, nausea, vomiting, and weight loss.

Stool culture often yields negative results, so the preferred diagnostic test is a stool ova and parasite (O&P) examination. This test should be repeated three times for accuracy. Additionally, the small bowel biopsy should be re-evaluated to check for the presence of Giardia lamblia.

The standard treatment for giardiasis involves antibiotic therapy with a nitroimidazole antibiotic, such as metronidazole.

This patient has presented with an Addisonian crisis, which is a rare but potentially catastrophic condition if not diagnosed promptly. The most likely underlying rheumatological diagnosis in this case is polymyalgia rheumatica, and it is likely that the GP started the patient on prednisolone medication.

Addison’s disease occurs when the adrenal glands underproduce steroid hormones, affecting the production of glucocorticoids, mineralocorticoids, and sex steroids. The main causes of Addison’s disease include autoimmune adrenalitis (accounting for 80% of cases), bilateral adrenalectomy, Waterhouse-Friderichsen syndrome (hemorrhage into the adrenal glands), and tuberculosis.

An Addisonian crisis is most commonly triggered by the deliberate or accidental withdrawal of steroid therapy in patients with Addison’s disease. Other factors that can precipitate a crisis include infection, trauma, myocardial infarction, cerebral infarction, asthma, hypothermia, and alcohol abuse.

The clinical features of Addison’s disease include weakness, lethargy, hypotension (especially orthostatic hypotension), nausea, vomiting, weight loss, reduced axillary and pubic hair, depression, and hyperpigmentation (particularly in palmar creases, buccal mucosa, and exposed areas). In an Addisonian crisis, the main features are usually hypoglycemia and shock, characterized by tachycardia, peripheral vasoconstriction, hypotension, altered consciousness, and coma.

Biochemically, Addison’s disease is characterized by increased ACTH levels (as a compensatory response to stimulate the adrenal glands), elevated serum renin levels, hyponatremia, hyperkalemia, hypercalcemia, hypoglycemia, and metabolic acidosis. Diagnostic investigations may include the Synacthen test, plasma ACTH level, plasma renin level, and adrenocortical antibodies.

Management of Addison’s disease should be overseen by an Endocrinologist. Typically, patients require hydrocortisone, fludrocortisone, and dehydroepiandrosterone. Some patients may also need thyroxine if there is hypothalamic-pituitary disease present. Treatment is lifelong, and patients should carry a steroid card and a MedicAlert bracelet, being aware of the possibility of an Addisonian crisis.

The Blatchford score, also known as the Glasgow-Blatchford Bleeding Score, is a commonly used tool to evaluate individuals who present with an acute upper gastrointestinal bleed. It is recommended by NICE (National Institute for Health and Care Excellence) that healthcare professionals use specific risk assessment scores for patients with this condition. The Blatchford score is used for initial assessment, while the full Rockall score is used after endoscopy.

The Blatchford score consists of 9 criteria, including gender, urea levels, hemoglobin levels, systolic blood pressure, pulse rate, presence of melena (black, tarry stools) at presentation, syncope (fainting) at presentation, presence of hepatic disease, and presence of cardiac failure. These criteria are used to determine the patient’s risk level. A calculator for the Blatchford score can be found in the links section.

Further Reading:

Peptic ulcer disease (PUD) is a condition characterized by a break in the mucosal lining of the stomach or duodenum. It is caused by an imbalance between factors that promote mucosal damage, such as gastric acid, pepsin, Helicobacter pylori infection, and NSAID drug use, and factors that maintain mucosal integrity, such as prostaglandins, mucus lining, bicarbonate, and mucosal blood flow.

The most common causes of peptic ulcers are H. pylori infection and NSAID use. Other factors that can contribute to the development of ulcers include smoking, alcohol consumption, certain medications (such as steroids), stress, autoimmune conditions, and tumors.

Diagnosis of peptic ulcers involves screening for H. pylori infection through breath or stool antigen tests, as well as upper gastrointestinal endoscopy. Complications of PUD include bleeding, perforation, and obstruction. Acute massive hemorrhage has a case fatality rate of 5-10%, while perforation can lead to peritonitis with a mortality rate of up to 20%.

The symptoms of peptic ulcers vary depending on their location. Duodenal ulcers typically cause pain that is relieved by eating, occurs 2-3 hours after eating and at night, and may be accompanied by nausea and vomiting. Gastric ulcers, on the other hand, cause pain that occurs 30 minutes after eating and may be associated with nausea and vomiting.

Management of peptic ulcers depends on the underlying cause and presentation. Patients with active gastrointestinal bleeding require risk stratification, volume resuscitation, endoscopy, and proton pump inhibitor (PPI) therapy. Those with perforated ulcers require resuscitation, antibiotic treatment, analgesia, PPI therapy, and urgent surgical review.

For stable patients with peptic ulcers, lifestyle modifications such as weight loss, avoiding trigger foods, eating smaller meals, quitting smoking, reducing alcohol consumption, and managing stress and anxiety are recommended. Medication review should be done to stop causative drugs if possible. PPI therapy, with or without H. pylori eradication therapy, is also prescribed. H. pylori testing is typically done using a carbon-13 urea breath test or stool antigen test, and eradication therapy involves a 7-day triple therapy regimen of antibiotics and PPI.

The patient in this case has been diagnosed with type 1 autoimmune hepatitis, also known as classic type autoimmune hepatitis. This condition is characterized by inflammation of the liver due to reduced levels of regulatory T-cells (Treg cells), leading to the production of autoantibodies against hepatocyte surface antigens. It primarily affects women (70%) between the ages of 15 and 40.

Autoimmune hepatitis causes chronic and progressive hepatitis, which eventually progresses to cirrhosis. Patients typically experience non-specific symptoms of malaise, but in some cases, the disease may present in its later stages with jaundice and severe illness. During this stage, liver function tests often show significantly elevated transaminases (ALT and AST), usually more than ten times the normal levels, and a normal or slightly elevated alkaline phosphatase (ALP). Around 80% of cases show positive antinuclear antibodies (ANA), while approximately 70% show positive smooth muscle antibodies (SMA). Antimitochondrial antibodies are usually low or absent.

There are four recognized subtypes of autoimmune hepatitis:
1. Type 1 (Classic type): Positive ANA and SMA, and grossly elevated IgG
2. Type 2: Positive liver kidney microsomal antibodies (affects children)
3. Type 3: Positive soluble liver antigen antibodies
4. Type 4: Seronegative

Treatment for autoimmune hepatitis involves the use of corticosteroids and/or azathioprine. Remission can be achieved in approximately 70% of cases. In some cases where drug therapy is not effective, liver transplantation may be necessary.

Primary sclerosing cholangitis (PSC) is a condition that affects the bile ducts, causing progressive inflammation and obstruction. It is characterized by recurrent episodes of cholangitis and progressive scarring of the bile ducts. PSC can ultimately lead to liver cirrhosis, liver failure, and hepatocellular carcinoma. There is a known association between PSC and ulcerative colitis, with more than 80% of PSC patients also having ulcerative colitis.

Primary biliary cirrhosis (PBC) is an autoimmune disease that results in the progressive destruction of the small bile ducts in the liver, primarily affecting the intralobular ducts. This leads to cholestatic jaundice, liver fibrosis, and eventually cirrhosis. PBC is more common in females (90%)

Clostridium difficile is a type of bacteria that is Gram-positive, anaerobic, and capable of forming spores. It is found in the intestines of about 3% of healthy adults, according to estimates from the UK Health Protection Agency in 2012.

Clostridium difficile associated diarrhea (CDAD) often occurs after the use of broad-spectrum antibiotics, which disrupt the normal bacteria in the gut and allow Clostridium difficile to multiply. This leads to inflammation and bleeding in the lining of the large intestine, resulting in a distinct pseudomembranous appearance. The majority of Clostridium difficile infections are reported in individuals over the age of 65.

The main symptoms of CDAD include abdominal cramps, severe bloody and/or watery diarrhea, offensive-smelling diarrhea, and fever.

The gold standard for diagnosing Clostridium difficile colitis is a cytotoxin assay. However, this test can be challenging to perform and results may take up to 48 hours to obtain. The most commonly used laboratory test for diagnosing Clostridium difficile colitis is an enzyme-mediated immunoassay that detects toxins A and B. This test has a specificity of 93-100% and a sensitivity of 63-99%.

In some cases, patients may develop a condition called toxic megacolon, which can be life-threatening, especially in frail or elderly individuals.

The current recommended first-line treatment for CDAD is oral vancomycin. For more information, refer to the guidance provided by the National Institute for Health and Care Excellence (NICE) regarding the risk of Clostridium difficile infection associated with the use of broad-spectrum antibiotics.

Lactulose and the oral antibiotic Rifaximin are commonly prescribed to patients with hepatic encephalopathy. The main goal of treatment for this condition is to identify and address any factors that may have triggered it. Lactulose is administered to relieve constipation, which can potentially lead to hepatic encephalopathy. On the other hand, Rifaximin is used to decrease the presence of enteric bacteria that produce ammonia.

Further Reading:

Cirrhosis is a condition where the liver undergoes structural changes, resulting in dysfunction of its normal functions. It can be classified as either compensated or decompensated. Compensated cirrhosis refers to a stage where the liver can still function effectively with minimal symptoms, while decompensated cirrhosis is when the liver damage is severe and clinical complications are present.

Cirrhosis develops over a period of several years due to repeated insults to the liver. Risk factors for cirrhosis include alcohol misuse, hepatitis B and C infection, obesity, type 2 diabetes, autoimmune liver disease, genetic conditions, certain medications, and other rare conditions.

The prognosis of cirrhosis can be assessed using the Child-Pugh score, which predicts mortality based on parameters such as bilirubin levels, albumin levels, INR, ascites, and encephalopathy. The score ranges from A to C, with higher scores indicating a poorer prognosis.

Complications of cirrhosis include portal hypertension, ascites, hepatic encephalopathy, variceal hemorrhage, increased infection risk, hepatocellular carcinoma, and cardiovascular complications.

Diagnosis of cirrhosis is typically done through liver function tests, blood tests, viral hepatitis screening, and imaging techniques such as transient elastography or acoustic radiation force impulse imaging. Liver biopsy may also be performed in some cases.

Management of cirrhosis involves treating the underlying cause, controlling risk factors, and monitoring for complications. Complications such as ascites, spontaneous bacterial peritonitis, oesophageal varices, and hepatic encephalopathy require specific management strategies.

Overall, cirrhosis is a progressive condition that requires ongoing monitoring and management to prevent further complications and improve outcomes for patients.

Ulcerative colitis can lead to various complications, although the development of fistulae is rare and less likely compared to other complications. Perianal complications associated with ulcerative colitis are uncommon and typically occur in cases with more extensive inflammation and a severe disease course.

The complications of ulcerative colitis can be categorized into localized and systemic complications. Localized complications include bleeding, electrolyte imbalance, toxic megacolon, perforation, an increased risk of colonic carcinoma, an increased risk of lymphoma, and the rare occurrence of stricture and fistula formation.

On the other hand, systemic complications of ulcerative colitis involve malnutrition and weight loss, iron-deficiency anemia, vitamin B12 deficiency, hypoproteinaemia, primary sclerosing cholangitis, primary biliary cirrhosis, chronic active hepatitis, joint pain or arthropathy, ankylosing spondylitis, pyoderma gangrenosum, and erythema nodosum. Additionally, ulcerative colitis can also lead to complications affecting the eyes, such as iritis, episcleritis, and uveitis.

Overall, while ulcerative colitis can present with various complications, the development of fistulae is rare and less likely compared to other complications. Perianal complications are infrequent and typically associated with more extensive inflammation and a severe disease course.

Infectious causes of bloody diarrhea include Campylobacter spp., Shigella spp., Salmonella spp., Clostridium difficile, Enterohaemorrhagic Escherichia coli, Yersinia spp., Schistosomiasis, and Amoebiasis (Entamoeba histolytica). Enterotoxigenic E.coli is a non-invasive strain that does not cause inflammation or bloody diarrhea. Instead, it typically presents with profuse watery diarrhea and is not usually associated with abdominal cramping. The other organisms mentioned in this question are associated with watery diarrhea, but not bloody diarrhea.

Traveller’s diarrhoea (TD) is a prevalent illness that affects travellers all around the globe. It is estimated that up to 50% of Europeans who spend two or more weeks in developing regions experience this condition. TD is characterized by the passage of three or more loose stools within a 24-hour period. Alongside this, individuals often experience abdominal cramps, nausea, and bloating.

Bacteria are the primary culprits behind approximately 80% of TD cases, while viruses and protozoa account for the remaining cases. Among the various organisms, Enterotoxigenic Escherichia coli (ETEC) is the most frequently identified cause.

In summary, TD is a common ailment that affects travellers, manifesting as loose stools, abdominal discomfort, and other associated symptoms. Bacterial infections, particularly ETEC, are the leading cause of this condition.

Wernicke’s encephalopathy is a sudden neurological condition that occurs due to a lack of thiamine (vitamin B1). It is characterized by symptoms such as confusion, difficulty with coordination, low body temperature, low blood pressure, involuntary eye movements, and vomiting.

Further Reading:

Alcoholic liver disease (ALD) is a spectrum of disease that ranges from fatty liver at one end to alcoholic cirrhosis at the other. Fatty liver is generally benign and reversible with alcohol abstinence, while alcoholic cirrhosis is a more advanced and irreversible form of the disease. Alcoholic hepatitis, which involves inflammation of the liver, can lead to the development of fibrotic tissue and cirrhosis.

Several factors can increase the risk of progression of ALD, including female sex, genetics, advanced age, induction of liver enzymes by drugs, and co-existent viral hepatitis, especially hepatitis C.

The development of ALD is multifactorial and involves the metabolism of alcohol in the liver. Alcohol is metabolized to acetaldehyde and then acetate, which can result in the production of damaging reactive oxygen species. Genetic polymorphisms and co-existing hepatitis C infection can enhance the pathological effects of alcohol metabolism.

Patients with ALD may be asymptomatic or present with non-specific symptoms such as abdominal discomfort, vomiting, or anxiety. Those with alcoholic hepatitis may have fever, anorexia, and deranged liver function tests. Advanced liver disease can manifest with signs of portal hypertension and cirrhosis, such as ascites, varices, jaundice, and encephalopathy.

Screening tools such as the AUDIT questionnaire can be used to assess alcohol consumption and identify hazardous or harmful drinking patterns. Liver function tests, FBC, and imaging studies such as ultrasound or liver biopsy may be performed to evaluate liver damage.

Management of ALD involves providing advice on reducing alcohol intake, administering thiamine to prevent Wernicke’s encephalopathy, and addressing withdrawal symptoms with benzodiazepines. Complications of ALD, such as intoxication, encephalopathy, variceal bleeding, ascites, hypoglycemia, and coagulopathy, require specialized interventions.

Heavy alcohol use can also lead to thiamine deficiency and the development of Wernicke Korsakoff’s syndrome, characterized by confusion, ataxia, hypothermia, hypotension, nystagmus, and vomiting. Prompt treatment is necessary to prevent progression to Korsakoff’s psychosis.

In summary, alcoholic liver disease is a spectrum of disease that can range from benign fatty liver to irreversible cirrhosis. Risk factors for progression include female sex, genetics, advanced age, drug-induced liver enzyme induction, and co-existing liver conditions.

Hepatic encephalopathy is a condition caused by the accumulation of nitrogenous waste products in the body due to impaired liver function. These waste products cross the blood brain barrier and contribute to the production of glutamine, leading to changes in astrocyte osmotic pressure, brain edema, and neurotransmitter dysfunction.

To address hepatic encephalopathy, the first-line drugs used are Rifaximin and lactulose. Rifaximin is an oral antibiotic that helps reduce the presence of ammonia-producing bacteria in the intestines. Lactulose, on the other hand, converts soluble ammonia into insoluble ammonium and aids in relieving constipation.

It is important to note that Chlordiazepoxide, a benzodiazepine, may be used to treat alcohol withdrawal but should be avoided in cases of hepatic encephalopathy as it can worsen the condition.

Further Reading:

Cirrhosis is a condition where the liver undergoes structural changes, resulting in dysfunction of its normal functions. It can be classified as either compensated or decompensated. Compensated cirrhosis refers to a stage where the liver can still function effectively with minimal symptoms, while decompensated cirrhosis is when the liver damage is severe and clinical complications are present.

Cirrhosis develops over a period of several years due to repeated insults to the liver. Risk factors for cirrhosis include alcohol misuse, hepatitis B and C infection, obesity, type 2 diabetes, autoimmune liver disease, genetic conditions, certain medications, and other rare conditions.

The prognosis of cirrhosis can be assessed using the Child-Pugh score, which predicts mortality based on parameters such as bilirubin levels, albumin levels, INR, ascites, and encephalopathy. The score ranges from A to C, with higher scores indicating a poorer prognosis.

Complications of cirrhosis include portal hypertension, ascites, hepatic encephalopathy, variceal hemorrhage, increased infection risk, hepatocellular carcinoma, and cardiovascular complications.

Diagnosis of cirrhosis is typically done through liver function tests, blood tests, viral hepatitis screening, and imaging techniques such as transient elastography or acoustic radiation force impulse imaging. Liver biopsy may also be performed in some cases.

Management of cirrhosis involves treating the underlying cause, controlling risk factors, and monitoring for complications. Complications such as ascites, spontaneous bacterial peritonitis, oesophageal varices, and hepatic encephalopathy require specific management strategies.

Overall, cirrhosis is a progressive condition that requires ongoing monitoring and management to prevent further complications and improve outcomes for patients.

In a young patient who has been experiencing diarrhea and abdominal pain for more than 6 weeks, it is important to consider inflammatory bowel disease as a possible diagnosis. The challenge lies in distinguishing between ulcerative colitis and Crohn’s disease. In this case, a biopsy was performed and the results showed transmural inflammation with the presence of non-caseating granulomas, which strongly suggests a diagnosis of Crohn’s disease.

To differentiate between ulcerative colitis and Crohn’s disease, it is helpful to consider the following characteristics. Ulcerative colitis typically only affects the rectum and colon, although the terminal ileum may be affected in some cases known as backwash ileitis. On the other hand, Crohn’s disease can affect any part of the gastrointestinal tract from the mouth to the anus, and there may be areas of normal mucosa between the affected areas, known as skip lesions.

There are also differences in the associations and systemic manifestations of these two conditions. Ulcerative colitis has a decreased incidence in smokers and is associated with liver conditions such as primary biliary cirrhosis, chronic active hepatitis, and primary sclerosing cholangitis. Crohn’s disease, on the other hand, has an increased incidence in smokers and is more commonly associated with systemic manifestations such as erythema nodosum, pyoderma gangrenosum, iritis/uveitis, cholelithiasis, and joint pain/arthropathy.

Pathologically, ulcerative colitis primarily affects the mucosa and submucosa, with the presence of mucosal ulcers, inflammatory cell infiltrate, and crypt abscesses. In contrast, Crohn’s disease is characterized by transmural inflammation, lymphoid aggregates, and neutrophil infiltrates. Non-caseating granulomas are seen in approximately 30% of cases, which is a distinguishing feature of Crohn’s disease.

When it comes to clinical features, abdominal pain is less prominent in ulcerative colitis, while bloody diarrhea is present in 90% of cases. The passage of mucus is also common, and fever may be present. Symptoms such as urgency, tenesmus (a feeling of incomplete bowel movement), and pre-defecation pain that is relieved by passing stools are frequently reported. In Crohn’s disease, abdominal pain is more prominent, and diarrhea is common, with the possibility of it being bloody.

In this scenario, a 35-year-old female presents to the emergency department with complaints of abdominal cramps and bloating. She mentions that she has not had a bowel movement for 2 days. After conducting blood tests, which all come back normal, and assessing her vital signs, which are also normal, it is suspected that she may have constipation predominant irritable bowel syndrome. This suspicion is based on her history of recurrent abdominal pain and bloating over the past 6-9 months, for which she has already consulted her primary care physician.

To address the constipation symptoms, a laxative is considered as a potential treatment option. However, it is important to exercise caution when prescribing medications for patients with irritable bowel syndrome. One medication that should be avoided in these patients is lactulose.

Further Reading:

Irritable bowel syndrome (IBS) is a chronic disorder that affects the interaction between the gut and the brain. The exact cause of IBS is not fully understood, but factors such as genetics, drug use, enteric infections, diet, and psychosocial factors are believed to play a role. The main symptoms of IBS include abdominal pain, changes in stool form and/or frequency, and bloating. IBS can be classified into subtypes based on the predominant stool type, including diarrhea-predominant, constipation-predominant, mixed, and unclassified.

Diagnosing IBS involves using the Rome IV criteria, which includes recurrent abdominal pain associated with changes in stool frequency and form. It is important to rule out other more serious conditions that may mimic IBS through a thorough history, physical examination, and appropriate investigations. Treatment for IBS primarily involves diet and lifestyle modifications. Patients are advised to eat regular meals with a healthy, balanced diet and adjust their fiber intake based on symptoms. A low FODMAP diet may be trialed, and a dietician may be consulted for guidance. Regular physical activity and weight management are also recommended.

Psychosocial factors, such as stress, anxiety, and depression, should be addressed and managed appropriately. If constipation is a predominant symptom, soluble fiber supplements or foods high in soluble fiber may be recommended. Laxatives can be considered if constipation persists, and linaclotide may be tried if optimal doses of previous laxatives have not been effective. Antimotility drugs like loperamide can be used for diarrhea, and antispasmodic drugs or low-dose tricyclic antidepressants may be prescribed for abdominal pain. If symptoms persist or are refractory to treatment, alternative diagnoses should be considered, and referral to a specialist may be necessary.

Overall, the management of IBS should be individualized based on the patient’s symptoms and psychosocial situation. Clear explanation of the condition and providing resources for patient education, such as the NHS patient information leaflet and support from organizations like The IBS Network, can also be beneficial.

The primary route of ethanol oxidation in the liver is through the alcohol dehydrogenase (ADH) pathway. Additionally, the accessory pathways of cytochrome P450 2E1 (CYP2E1) and catalase also play a role in the oxidative metabolism of alcohol.

Further Reading:

Alcoholic liver disease (ALD) is a spectrum of disease that ranges from fatty liver at one end to alcoholic cirrhosis at the other. Fatty liver is generally benign and reversible with alcohol abstinence, while alcoholic cirrhosis is a more advanced and irreversible form of the disease. Alcoholic hepatitis, which involves inflammation of the liver, can lead to the development of fibrotic tissue and cirrhosis.

Several factors can increase the risk of progression of ALD, including female sex, genetics, advanced age, induction of liver enzymes by drugs, and co-existent viral hepatitis, especially hepatitis C.

The development of ALD is multifactorial and involves the metabolism of alcohol in the liver. Alcohol is metabolized to acetaldehyde and then acetate, which can result in the production of damaging reactive oxygen species. Genetic polymorphisms and co-existing hepatitis C infection can enhance the pathological effects of alcohol metabolism.

Patients with ALD may be asymptomatic or present with non-specific symptoms such as abdominal discomfort, vomiting, or anxiety. Those with alcoholic hepatitis may have fever, anorexia, and deranged liver function tests. Advanced liver disease can manifest with signs of portal hypertension and cirrhosis, such as ascites, varices, jaundice, and encephalopathy.

Screening tools such as the AUDIT questionnaire can be used to assess alcohol consumption and identify hazardous or harmful drinking patterns. Liver function tests, FBC, and imaging studies such as ultrasound or liver biopsy may be performed to evaluate liver damage.

Management of ALD involves providing advice on reducing alcohol intake, administering thiamine to prevent Wernicke’s encephalopathy, and addressing withdrawal symptoms with benzodiazepines. Complications of ALD, such as intoxication, encephalopathy, variceal bleeding, ascites, hypoglycemia, and coagulopathy, require specialized interventions.

Heavy alcohol use can also lead to thiamine deficiency and the development of Wernicke Korsakoff’s syndrome, characterized by confusion, ataxia, hypothermia, hypotension, nystagmus, and vomiting. Prompt treatment is necessary to prevent progression to Korsakoff’s psychosis.

In summary, alcoholic liver disease is a spectrum of disease that can range from benign fatty liver to irreversible cirrhosis. Risk factors for progression include female sex, genetics, advanced age, drug-induced liver enzyme induction, and co-existing liver conditions.

C. difficile diarrhoea is typically diagnosed by testing a stool sample for the presence of its toxin using the cytotoxin assay. This patient has several risk factors for developing c.diff diarrhoea, including recent use of broad spectrum antibiotics, being over the age of 65, and residing in a nursing home. The gold standard for diagnosing c.diff diarrhoea is the detection of exotoxin in the stool using the cytotoxin assay. The C13 urea breath test is used to detect h.pylori infection, while stool antigen testing is commonly used to detect h.pylori as well as rotavirus and other viral causes of gastroenteritis. Stool microscopy is utilized to identify the presence of parasitic organisms such as protozoa and helminths.

Further Reading:

Clostridium difficile (C.diff) is a gram positive rod commonly found in hospitals. Some strains of C.diff produce exotoxins that can cause intestinal damage, leading to pseudomembranous colitis. This infection can range from mild diarrhea to severe illness. Antibiotic-associated diarrhea is often caused by C.diff, with 20-30% of cases being attributed to this bacteria. Antibiotics such as clindamycin, cephalosporins, fluoroquinolones, and broad-spectrum penicillins are frequently associated with C.diff infection.

Clinical features of C.diff infection include diarrhea, distinctive smell, abdominal pain, raised white blood cell count, and in severe cases, toxic megacolon. In some severe cases, diarrhea may be absent due to the infection causing paralytic ileus. Diagnosis is made by detecting Clostridium difficile toxin (CDT) in the stool. There are two types of exotoxins produced by C.diff, toxin A and toxin B, which cause mucosal damage and the formation of a pseudomembrane in the colon.

Risk factors for developing C.diff infection include age over 65, antibiotic treatment, previous C.diff infection, exposure to infected individuals, proton pump inhibitor or H2 receptor antagonist use, prolonged hospitalization or residence in a nursing home, and chronic disease or immunosuppression. Complications of C.diff infection can include toxic megacolon, colon perforation, sepsis, and even death, especially in frail elderly individuals.

Management of C.diff infection involves stopping the causative antibiotic if possible, optimizing hydration with IV fluids if necessary, and assessing the severity of the infection. Treatment options vary based on severity, ranging from no antibiotics for mild cases to vancomycin or fidaxomicin for moderate cases, and hospital protocol antibiotics (such as oral vancomycin with IV metronidazole) for severe or life-threatening cases. Severe cases may require admission under gastroenterology or GI surgeons.

Diagnosing spontaneous bacterial peritonitis (SBP) requires an abdominal paracentesis of ascitic tap. Other reasons for performing a diagnostic tap include determining the cause of ascites, distinguishing between transudate and exudate, and detecting cancerous cells. Additionally, a therapeutic paracentesis can be done to alleviate respiratory distress or abdominal pain caused by the ascites.

However, there are certain contraindications to consider. These include having an uncooperative patient, a skin infection at the proposed puncture site, being pregnant, or experiencing severe bowel distension. Relative contraindications involve having severe thrombocytopenia (platelet count less than 20 x 103/μL) or coagulopathy (INR greater than 2.0).

For patients with an INR greater than 2.0, it is recommended to administer fresh frozen plasma (FFP) before the procedure. One approach is to infuse one unit of fresh frozen plasma prior to the procedure and then proceed with the paracentesis while the second unit is being infused.

In the case of patients with a platelet count lower than 20 x 103/μL, it is advisable to provide a platelet infusion before the procedure.

In a young patient who has been experiencing bloody diarrhea for more than 6 weeks, it is important to consider inflammatory bowel disease as a possible diagnosis. The challenge lies in distinguishing between ulcerative colitis and Crohn’s disease. In this case, a biopsy was performed and the results showed the presence of inflammatory cell infiltrate and crypt abscesses, which strongly suggests a diagnosis of ulcerative colitis.

Ulcerative colitis:
– Typically affects only the rectum and colon
– The terminal ileum may be affected if backwash ileitis occurs
– Does not have skip lesions (areas of normal mucosa between affected areas)
– Decreased incidence in smokers
– Common associations include liver conditions such as primary biliary cirrhosis, chronic active hepatitis, and primary sclerosing cholangitis
– Other systemic manifestations are less common compared to Crohn’s disease
– Pathological features include primarily affecting the mucosa and submucosa, presence of mucosal ulcers, inflammatory cell infiltrate, and crypt abscesses
– Clinical features include less prominent abdominal pain, bloody diarrhea in 90% of cases, passage of mucus, and possible fever
– Barium studies may show a granular appearance, button-shaped ulcers, and loss of normal haustral markings
– Complications include a 20-fold increase in the 20-year risk of colonic carcinoma, iron deficiency anemia, and rare occurrence of fistulae

Crohn’s disease:
– Can affect any part of the gastrointestinal tract from the mouth to the anus
– May have skip lesions of normal mucosa between affected areas
– Increased incidence in smokers
– Systemic manifestations are more common compared to ulcerative colitis, including erythema nodosum, pyoderma gangrenosum, iritis/uveitis, cholelithiasis, and joint pain/arthropathy
– Pathological features include transmural inflammation, presence of lymphoid aggregates and neutrophil infiltrates, and non-caseating granulomas seen in 30% of cases
– Clinical features include more prominent abdominal pain, common occurrence of diarrhea (which can also be bloody), frequent and oral lesions, and possible fever
– Barium studies may show severe mucosal ulcers

Traveller’s diarrhoea (TD) is a prevalent illness that affects travellers all around the world. It is estimated that up to 50% of Europeans who spend two or more weeks in developing regions experience TD. This condition is characterized by the passage of three or more loose stools within a 24-hour period. Typically, individuals with TD also experience abdominal cramps, nausea, and bloating.

In most cases of gastroenteritis, there is no need for stool microscopy and culture. However, it is advisable to arrange these tests if the patient has recently returned from overseas travel, is severely ill, has prolonged symptoms, comes from an institution, or works as a food handler.

Bacteria are responsible for approximately 80% of TD cases, while viruses and protozoa account for the remaining cases. The most common causative organism is Escherichia coli, with Enterohaemorrhagic Escherichia coli being the strain most likely to cause bloody diarrhoea.

Infective causes of bloody diarrhoea include Campylobacter jejuni, Shigella spp., Salmonella spp., Clostridium difficile, Yersinia spp., Schistosomiasis, and Amoebiasis (Entamoeba histolytica).

Clostridium difficile is a type of bacteria that is Gram-positive, anaerobic, and capable of forming spores. When individuals take broad-spectrum antibiotics, it can disrupt the normal bacteria in the bowel and allow C. difficile to multiply. This can lead to inflammation and bleeding in the mucosa of the large intestine, resulting in a distinct appearance known as pseudomembranous. The main symptoms of C. difficile infection (CDI) include abdominal cramps, bloody and/or watery diarrhea, and fever. It is worth noting that the majority of CDI cases occur in individuals over the age of 65.

CDI is considered to be the most severe consequence of antibiotic treatment and is now a significant cause of illness and death. While CDI can occur after treatment with any antibiotic, the risk is particularly high with prolonged use of broad-spectrum antibiotics. Recently, two research groups conducted a meta-analysis to assess the risk associated with different classes of antibiotics.

Their findings revealed that the risk of CDI increased nearly sevenfold after antibiotic treatment (odds ratio, 6.91). Among the various antibiotic classes, clindamycin posed the greatest risk (odds ratio, 20.43), followed by fluoroquinolones (odds ratio, 5.65), cephalosporins (odds ratio, 4.47), penicillins (odds ratio, 3.25), macrolides (odds ratio, 2.55), and trimethoprim/sulfonamides (odds ratio, 1.84). Tetracyclines, on the other hand, were not found to be associated with an increased risk of CDI (odds ratio, 0.91).

For more information on this topic, you may consider reading the article Antibiotic Classes and Risk for Clostridium difficile Infection.

If the serum ascites albumin gradient (SAAG) is greater than 1.1 g/dL (or >11 g/L), it means that the ascites is caused by portal hypertension. On the other hand, a low gradient SAAG (< 1.1 g/dL or <11 g/L) indicates that the ascites is not associated with increased portal pressure and may be caused by conditions such as tuberculosis, pancreatitis, infections, serositis, various types of peritoneal cancers (peritoneal carcinomatosis), and pulmonary infarcts. Further Reading: Cirrhosis is a condition where the liver undergoes structural changes, resulting in dysfunction of its normal functions. It can be classified as either compensated or decompensated. Compensated cirrhosis refers to a stage where the liver can still function effectively with minimal symptoms, while decompensated cirrhosis is when the liver damage is severe and clinical complications are present. Cirrhosis develops over a period of several years due to repeated insults to the liver. Risk factors for cirrhosis include alcohol misuse, hepatitis B and C infection, obesity, type 2 diabetes, autoimmune liver disease, genetic conditions, certain medications, and other rare conditions. The prognosis of cirrhosis can be assessed using the Child-Pugh score, which predicts mortality based on parameters such as bilirubin levels, albumin levels, INR, ascites, and encephalopathy. The score ranges from A to C, with higher scores indicating a poorer prognosis. Complications of cirrhosis include portal hypertension, ascites, hepatic encephalopathy, variceal hemorrhage, increased infection risk, hepatocellular carcinoma, and cardiovascular complications. Diagnosis of cirrhosis is typically done through liver function tests, blood tests, viral hepatitis screening, and imaging techniques such as transient elastography or acoustic radiation force impulse imaging. Liver biopsy may also be performed in some cases. Management of cirrhosis involves treating the underlying cause, controlling risk factors, and monitoring for complications. Complications such as ascites, spontaneous bacterial peritonitis, oesophageal varices, and hepatic encephalopathy require specific management strategies. Overall, cirrhosis is a progressive condition that requires ongoing monitoring and management to prevent further complications and improve outcomes for patients.

Hepatitis B surface antigen (HBsAg) is a protein found on the surface of the hepatitis B virus. It is the first marker to appear in the blood after exposure to the virus, usually within 1 to 2 weeks. Symptoms of hepatitis B typically develop around 4 weeks after exposure. HBsAg can be detected in high levels in the blood during both acute and chronic hepatitis B infections. Its presence indicates that the person is infectious and can transmit the virus to others. The body naturally produces antibodies to HBsAg as part of the immune response to the infection. In fact, HBsAg is used to create the hepatitis B vaccine.

Hepatitis B surface antibody (anti-HBs) indicates that a person has recovered from a hepatitis B infection and is now immune to the virus. It can also develop in individuals who have been successfully vaccinated against hepatitis B.

Total hepatitis B core antibody (anti-HBc) appears at the onset of symptoms in acute hepatitis B and remains detectable for life. Its presence indicates that a person has either had a previous or ongoing infection with the hepatitis B virus, although the exact timing of the infection cannot be determined. Anti-HBc is not present in individuals who have received the hepatitis B vaccine.

IgM antibody to hepatitis B core antigen (IgM anti-HBc) indicates a recent or acute infection with the hepatitis B virus, typically within the past 6 months.

Primary sclerosing cholangitis (PSC) is a condition that affects the bile ducts, causing inflammation and blockage over time. It is more commonly seen in men than women, with a ratio of 3 to 1, and is typically diagnosed around the age of 40. PSC is characterized by recurring episodes of cholangitis and progressive scarring of the bile ducts. If left untreated, it can lead to liver cirrhosis, liver failure, and even hepatocellular carcinoma. PSC is often associated with ulcerative colitis, with more than 80% of PSC patients also having this condition. Other associations include fibrosis in the retroperitoneal and mediastinal areas.

When performing an endoscopic retrograde cholangiopancreatography (ERCP) to diagnose PSC, certain findings are typically observed. These include ulceration of the common bile duct, irregular narrowing with saccular dilatation above the structured ducts (resembling beads-on-a-string or a beaded appearance), and involvement of both the intra- and extrahepatic ducts simultaneously.

Complications that can arise from PSC include liver cirrhosis, portal hypertension, liver failure, and cholangiocarcinoma. Treatment options for PSC include the use of ursodeoxycholic acid to improve symptoms and liver function (although it does not affect the overall prognosis), cholestyramine to alleviate itching, and correction of deficiencies in fat-soluble vitamins. In some cases, endoscopic dilatation of strictures may be necessary.

Liver transplantation is the definitive treatment for PSC. The 10-year survival rate after transplantation is approximately 65%, and the average survival time from the time of diagnosis is around seven years. Patients with PSC often succumb to complications such as secondary biliary cirrhosis, portal hypertension, or cholangitis. Additionally, about 10% of PSC patients will develop cholangiocarcinoma.

Peptic ulcer disease is most commonly caused by NSAIDs, making them the leading drug cause. However, h.pylori infection is the primary cause of peptic ulcers, with NSAIDs being the second most common cause.

Further Reading:

Peptic ulcer disease (PUD) is a condition characterized by a break in the mucosal lining of the stomach or duodenum. It is caused by an imbalance between factors that promote mucosal damage, such as gastric acid, pepsin, Helicobacter pylori infection, and NSAID drug use, and factors that maintain mucosal integrity, such as prostaglandins, mucus lining, bicarbonate, and mucosal blood flow.

The most common causes of peptic ulcers are H. pylori infection and NSAID use. Other factors that can contribute to the development of ulcers include smoking, alcohol consumption, certain medications (such as steroids), stress, autoimmune conditions, and tumors.

Diagnosis of peptic ulcers involves screening for H. pylori infection through breath or stool antigen tests, as well as upper gastrointestinal endoscopy. Complications of PUD include bleeding, perforation, and obstruction. Acute massive hemorrhage has a case fatality rate of 5-10%, while perforation can lead to peritonitis with a mortality rate of up to 20%.

The symptoms of peptic ulcers vary depending on their location. Duodenal ulcers typically cause pain that is relieved by eating, occurs 2-3 hours after eating and at night, and may be accompanied by nausea and vomiting. Gastric ulcers, on the other hand, cause pain that occurs 30 minutes after eating and may be associated with nausea and vomiting.

Management of peptic ulcers depends on the underlying cause and presentation. Patients with active gastrointestinal bleeding require risk stratification, volume resuscitation, endoscopy, and proton pump inhibitor (PPI) therapy. Those with perforated ulcers require resuscitation, antibiotic treatment, analgesia, PPI therapy, and urgent surgical review.

For stable patients with peptic ulcers, lifestyle modifications such as weight loss, avoiding trigger foods, eating smaller meals, quitting smoking, reducing alcohol consumption, and managing stress and anxiety are recommended. Medication review should be done to stop causative drugs if possible. PPI therapy, with or without H. pylori eradication therapy, is also prescribed. H. pylori testing is typically done using a carbon-13 urea breath test or stool antigen test, and eradication therapy involves a 7-day triple therapy regimen of antibiotics and PPI.

When a variceal bleed is suspected, it is important to start treatment with either terlipressin or somatostatin as soon as possible. These medications help control the bleeding and are typically continued for 3-5 days if variceal haemorrhage is confirmed. Additionally, an upper GI endoscopy may be performed to either band the varices or inject a sclerosing agent to stop the bleeding. If the bleeding is difficult to control, a Sengstaken-Blakemore tube may be inserted until further treatment can be administered. Once the bleeding is under control and the patient has been resuscitated, antibiotic prophylaxis should be prescribed. Ceftriaxone or fluoroquinolones are commonly used for this purpose. Proton pump inhibitors are not recommended unless there is a specific need for treating peptic ulcer disease. Beta blockers like carvedilol are used to prevent variceal bleeding but are not effective in treating active bleeding. Vitamin K is typically not used in the acute setting of variceal bleeding.

Further Reading:

Cirrhosis is a condition where the liver undergoes structural changes, resulting in dysfunction of its normal functions. It can be classified as either compensated or decompensated. Compensated cirrhosis refers to a stage where the liver can still function effectively with minimal symptoms, while decompensated cirrhosis is when the liver damage is severe and clinical complications are present.

Cirrhosis develops over a period of several years due to repeated insults to the liver. Risk factors for cirrhosis include alcohol misuse, hepatitis B and C infection, obesity, type 2 diabetes, autoimmune liver disease, genetic conditions, certain medications, and other rare conditions.

The prognosis of cirrhosis can be assessed using the Child-Pugh score, which predicts mortality based on parameters such as bilirubin levels, albumin levels, INR, ascites, and encephalopathy. The score ranges from A to C, with higher scores indicating a poorer prognosis.

Complications of cirrhosis include portal hypertension, ascites, hepatic encephalopathy, variceal hemorrhage, increased infection risk, hepatocellular carcinoma, and cardiovascular complications.

Diagnosis of cirrhosis is typically done through liver function tests, blood tests, viral hepatitis screening, and imaging techniques such as transient elastography or acoustic radiation force impulse imaging. Liver biopsy may also be performed in some cases.

Management of cirrhosis involves treating the underlying cause, controlling risk factors, and monitoring for complications. Complications such as ascites, spontaneous bacterial peritonitis, oesophageal varices, and hepatic encephalopathy require specific management strategies.

Overall, cirrhosis is a progressive condition that requires ongoing monitoring and management to prevent further complications and improve outcomes for patients.

Spontaneous bacterial peritonitis (SBP) is a sudden bacterial infection of the fluid in the abdomen. It typically occurs in patients with high blood pressure in the portal vein, and about 70% of cases are seen in patients with severe liver disease. In any given year, around 30% of patients with fluid buildup in the abdomen will develop SBP.

SBP can present with a wide range of symptoms, so it’s important to be vigilant when caring for patients with fluid buildup in the abdomen, especially if there is a sudden decline in their condition. Some patients may not show any symptoms at all.

Common clinical features of SBP include fever (80% of cases), abdominal pain (70% of cases), worsening or unexplained confusion due to liver dysfunction, diarrhea, nausea and vomiting, and bowel obstruction.

There are several factors that increase the risk of developing SBP, including severe liver disease (Child-Pugh class C), gastrointestinal bleeding, urinary tract infection, excessive growth of bacteria in the intestines, presence of indwelling lines such as central venous catheters or urinary catheters, previous episodes of SBP, and low levels of protein in the fluid buildup in the abdomen.

To diagnose SBP, a procedure called abdominal paracentesis is performed to collect fluid from the abdomen. The following findings on fluid analysis strongly suggest SBP: total white blood cell count in the fluid greater than 500 cells/µL, total neutrophil count in the fluid greater than 250 cells/µL, lactate level in the fluid higher than 25 mg/dL, pH of the fluid below 7.35, and presence of bacteria on Gram-stain.

Patients with SBP should be admitted to the hospital and treated with broad-spectrum antibiotics. The preferred antibiotic is an intravenous third-generation cephalosporin, such as Ceftriaxone. If the patient is allergic to beta-lactam antibiotics, ciprofloxacin can be considered as an alternative. Administration of intravenous albumin has been shown to reduce the risk of kidney failure and death.

This patient has been diagnosed with primary biliary cirrhosis (PBC). PBC is a liver disease caused by an autoimmune response, leading to the progressive destruction of the small bile ducts in the liver. The damage primarily affects the intralobular ducts. As a result, the patient experiences cholestatic jaundice, followed by liver fibrosis and cirrhosis. PBC is more common in females, with 90% of patients being women. It typically occurs between the ages of 30 and 65. Liver function tests show elevated levels of alkaline phosphatase (ALP), often before any symptoms appear. Antimitochondrial antibodies are positive in 95% of cases. Around 50% of patients have smooth muscle antibodies (SMA), and approximately 20% have antinuclear antibodies (ANA). IgM levels are raised in over 80% of cases.

Autoimmune hepatitis is liver inflammation caused by a decrease in regulatory T-cells (Treg cells), leading to the production of autoantibodies against hepatocyte surface antigens. It mainly affects women (70%) between the ages of 15 and 40. The condition causes chronic, progressive hepatitis, which eventually progresses to cirrhosis. Patients typically present with non-specific symptoms of malaise, although in some cases, the disease may be more advanced, resulting in jaundice and severe illness. In later stages, liver function tests show significantly elevated levels of transaminases (ALT and AST), often exceeding ten times the normal range. Alkaline phosphatase (ALP) levels are usually normal or slightly elevated. Antinuclear antibodies (ANA) are positive in approximately 80% of cases, while smooth muscle antibodies (SMA) are positive in around 70% of cases. Antimitochondrial antibodies are typically low or absent.

Primary sclerosing cholangitis (PSC) is a condition that causes progressive inflammation and obstruction of the bile ducts. It is characterized by recurrent episodes of cholangitis and the gradual scarring of the bile ducts. PSC can eventually lead to liver cirrhosis, liver failure, and hepatocellular carcinoma. There is a known association between PSC and ulcerative colitis, with over 80% of PSC patients also having ulcerative colitis.

Hepatic damage caused by hydroxychloroquine is extremely rare.

The process of alcohol oxidation involves two steps. Firstly, alcohol is converted into acetaldehyde, and then acetaldehyde is further converted into acetate. During the oxidation of acetaldehyde, reactive oxygen species are produced along with acetate. This oxidation process is facilitated by three enzyme systems: catalase, CYPE21, and alcohol dehydrogenase. NAD+ acts as a coenzyme for alcohol dehydrogenase during this entire process.

Further Reading:

Alcoholic liver disease (ALD) is a spectrum of disease that ranges from fatty liver at one end to alcoholic cirrhosis at the other. Fatty liver is generally benign and reversible with alcohol abstinence, while alcoholic cirrhosis is a more advanced and irreversible form of the disease. Alcoholic hepatitis, which involves inflammation of the liver, can lead to the development of fibrotic tissue and cirrhosis.

Several factors can increase the risk of progression of ALD, including female sex, genetics, advanced age, induction of liver enzymes by drugs, and co-existent viral hepatitis, especially hepatitis C.

The development of ALD is multifactorial and involves the metabolism of alcohol in the liver. Alcohol is metabolized to acetaldehyde and then acetate, which can result in the production of damaging reactive oxygen species. Genetic polymorphisms and co-existing hepatitis C infection can enhance the pathological effects of alcohol metabolism.

Patients with ALD may be asymptomatic or present with non-specific symptoms such as abdominal discomfort, vomiting, or anxiety. Those with alcoholic hepatitis may have fever, anorexia, and deranged liver function tests. Advanced liver disease can manifest with signs of portal hypertension and cirrhosis, such as ascites, varices, jaundice, and encephalopathy.

Screening tools such as the AUDIT questionnaire can be used to assess alcohol consumption and identify hazardous or harmful drinking patterns. Liver function tests, FBC, and imaging studies such as ultrasound or liver biopsy may be performed to evaluate liver damage.

Management of ALD involves providing advice on reducing alcohol intake, administering thiamine to prevent Wernicke’s encephalopathy, and addressing withdrawal symptoms with benzodiazepines. Complications of ALD, such as intoxication, encephalopathy, variceal bleeding, ascites, hypoglycemia, and coagulopathy, require specialized interventions.

Heavy alcohol use can also lead to thiamine deficiency and the development of Wernicke Korsakoff’s syndrome, characterized by confusion, ataxia, hypothermia, hypotension, nystagmus, and vomiting. Prompt treatment is necessary to prevent progression to Korsakoff’s psychosis.

In summary, alcoholic liver disease is a spectrum of disease that can range from benign fatty liver to irreversible cirrhosis. Risk factors for progression include female sex, genetics, advanced age, drug-induced liver enzyme induction, and co-existing liver conditions.